<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119333">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896570</url>
  </required_header>
  <id_info>
    <org_study_id>Ciritical endpoint HH</org_study_id>
    <nct_id>NCT01896570</nct_id>
  </id_info>
  <brief_title>Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF</brief_title>
  <official_title>The Prognostic Role of Subsequent Atrial Tachycardias Occurring After Atrial Fibrillation Termination: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: ethics committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to examine the prognostic role of subsequent Atrial
      Tachycardias (ATs) in the mechanisms of atrial fibrillation (AF). Therefore, the
      investigators compare patients who were randomly assigned to either undergo cardioversion
      after AF has been terminated to AT or further ablation until the achievement of sinus
      rhythm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Arrhythmia-free survival</measure>
    <time_frame>24 months after enrolment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of Arrhythmia recurrence</measure>
    <time_frame>24 months after enrolement</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>after blanking period (3 months) until study end (at least 24 months)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">110</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group A: cardioversion at AT</arm_group_label>
    <description>after achievement of AT, pts were cardioverted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: ablation to SR</arm_group_label>
    <description>After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation of subsequent atrial tachycardia</intervention_name>
    <arm_group_label>Group B: ablation to SR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent AF
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistent AF for at least 1 months,

          -  age &gt; 18 years,

          -  refractory to drug therapy,

          -  no prior ablation

        Exclusion Criteria:

          -  prior AF ablation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Eppendorf, Dept. of Electrophysiology</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 10, 2013</lastchanged_date>
  <firstreceived_date>July 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Thomas Rostock</investigator_full_name>
    <investigator_title>Univ.-Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>subsequent atrial tachycardia</keyword>
  <keyword>mechanisms</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
